Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Malaysia ETF (EWM) vs Medpace Holdings Inc (MEDP) Price & Performance

iShares MSCI Malaysia ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Malaysia ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI Malaysia ETF trades at $28.28, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals.

EWMMEDP
Sector
Broad Market / FactorTechnology
52-Week High
$30.42$620.59
52-Week Low
$24.73$393.42
Market Cap
$16.90B
Enterprise Value
$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Malaysia ETF

EWM, the iShares MSCI Malaysia ETF, trades at $28.28, up 0.86% today, with a bearish technical signal from moving averages and oscillators neutral. The ETF is heavily weighted in Financials (54%) and Industrials (21%). Recent news highlights Malaysia's data center expansion, semiconductor ambitions, and tourism initiatives as growth drivers, though the country faces energy supply challenges amid rising power demand.

Outlook is mixed: Malaysia's economic initiatives offer potential upside, but energy constraints and concentrated sector exposure pose risks. The ETF provides targeted emerging market access, with investor sentiment cautious due to macroeconomic uncertainties and technical weakness.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Malaysia ETF

EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.

Read more on EWM

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP